Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia

Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents. We found previously that the effect of decitabine on hematopoietic stem cell viability differed between Mll5 wild-type and null cells. We, therefore, investigated the role of MLL5 expression levels on outcome of acute myeloid leukemia patients who were treated with decitabine. MLL5 above the median expression level predicted longer overall survival independent of DNMT3A mutation status in bivariate analysis (median overall survival for high vs. low MLL5 expression 292 vs. 167 days; P=0.026). In patients who received three or more courses decitabine, high MLL5 expression and wild-type DNMT3A independently predicted improved overall survival (median overall survival for high vs. low MLL5 expression 468 vs. 243 days; P=0.012). In transformed murine cells, loss of Mll5 was associated with resistance to low-dose decitabine, less global DNA methylation in promoter regions, and reduced DNA demethylation upon decitabine treatment. Together, these data support our clinical observation of improved outcome in decitabine-treated patients who express MLL5 at high levels, and suggest a mechanistic role of MLL5 in the regulation of DNA methylation.

[1]  Ulrich Lehmann,et al.  Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. , 2013, Blood.

[2]  M. Groudine,et al.  Molecular basis for chromatin binding and regulation of MLL5 , 2013, Proceedings of the National Academy of Sciences.

[3]  Chuangui Wang,et al.  Mixed Lineage Leukemia 5 (MLL5) Protein Regulates Cell Cycle Progression and E2F1-responsive Gene Expression via Association with Host Cell Factor-1 (HCF-1)* , 2013, The Journal of Biological Chemistry.

[4]  Cheryl F. Lichti,et al.  Genomic impact of transient low-dose decitabine treatment on primary AML cells. , 2013, Blood.

[5]  E. Solary,et al.  TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS , 2013, The EMBO journal.

[6]  B. Teh,et al.  Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer , 2012, Science Translational Medicine.

[7]  Pearlly Yan,et al.  Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. , 2012, Blood.

[8]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[9]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Bloomfield,et al.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia , 2012, Leukemia.

[11]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[12]  K. Döhner,et al.  A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy , 2012, Haematologica.

[13]  K. Wagner,et al.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Nicola K. Wilson,et al.  Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. , 2011, Cancer cell.

[15]  B. Quesnel,et al.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.

[16]  K. Döhner,et al.  Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Vyas,et al.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.

[18]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Melnick,et al.  Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. , 2011, Blood.

[20]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[21]  Y. Liou,et al.  Phosphorylation of Mixed Lineage Leukemia 5 by Cdc2 Affects Its Cellular Distribution and Is Required for Mitotic Entry* , 2010, The Journal of Biological Chemistry.

[22]  Helen Brady,et al.  A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines , 2010, PloS one.

[23]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[24]  G. Pavlath,et al.  MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation , 2009, Proceedings of the National Academy of Sciences.

[25]  S. Aparicio,et al.  Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. , 2009, Blood.

[26]  K. Döhner,et al.  Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. , 2009, Blood.

[27]  N. Killeen,et al.  MLL5 contributes to hematopoietic stem cell fitness and homeostasis. , 2009, Blood.

[28]  Bas J. Wouters,et al.  Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling , 2009, Haematologica.

[29]  G. Pavlath,et al.  A gene-trap strategy identifies quiescence-induced genes in synchronized myoblasts , 2008, Journal of Biosciences.

[30]  J. Dipersio,et al.  Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) , 2008, Cancer Chemotherapy and Pharmacology.

[31]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[32]  W. Lam,et al.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.

[33]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[34]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[35]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[36]  J. Strominger,et al.  MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[38]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[39]  E. Green,et al.  MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia , 2002, Oncogene.

[40]  C. Croce,et al.  Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.

[41]  K. Calvo,et al.  Hoxa9 Immortalizes a Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Promyelocyte Capable of Biphenotypic Differentiation to Neutrophils or Macrophages, Independent of Enforced Meis Expression , 2000, Molecular and Cellular Biology.

[42]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[43]  Unnur Thorsteinsdottir,et al.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.

[44]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[46]  E. Solary,et al.  TET 2 and TET 3 regulate GlcNAcylation and H 3 K 4 methylation through OGT and SET 1 / COMPASS , 2013 .

[47]  John M Greally,et al.  Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. , 2009, Methods in molecular biology.

[48]  Jie Liu,et al.  RNA interference against mixed lineage leukemia 5 resulted in cell cycle arrest. , 2008, The international journal of biochemistry & cell biology.

[49]  B. Löwenberg.  Acute myeloid leukemia: the challenge of capturing disease variety. , 2008, Hematology. American Society of Hematology. Education Program.

[50]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[51]  S. Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[52]  T. Speed,et al.  Statistical issues in cDNA microarray data analysis. , 2003, Methods in molecular biology.

[53]  D. Cox.  Regression Models and Life-Tables , 1972 .